The World Health Organization issued updated guidance cautioning against the use of obesity medications and GLP-1 weight-loss injections in children younger than 10 years old. The recommendation specifically targets medications such as Mounjaro and Wegovy, though most of these drugs are only officially licensed for older children and adolescents. The organization notes that some physicians prescribe these medications off-label to younger children, and pharmaceutical companies are currently conducting clinical trials with children as young as six.
According to WHO leadership, treatment for obesity in this youngest age group should prioritize lifestyle interventions centered on nutrition and physical activity rather than pharmaceutical or surgical approaches. The organization does not oppose the continuation of research trials examining these treatments. WHO indicated that certain digital tools, including activity trackers and interactive games designed to promote physical movement, may offer limited benefits based on available evidence.
Global obesity prevalence in children and adolescents has reached significant levels, with approximately 170 million affected worldwide. The organization highlighted that 70 million children aged 5 to 9 are obese, representing a dramatic increase from previous decades. Specifically, obesity rates in the 5-to-9 age group have increased fourfold since 1990, moving from 2% to 8%. Additionally, 35 million children under age five were classified as overweight. Obesity elevates the risk of numerous health conditions, including type 2 diabetes.
Dr. Luz De Rigil, WHO’s Director of Nutrition and Food Safety, emphasized that the organization does not recommend obesity medications, bariatric surgery, or weight-management devices for children under 10, characterizing this as a strong recommendation. Officials acknowledged that treatment with these approaches may warrant consideration for older children and adolescents when lifestyle modifications prove ineffective and when individuals demonstrate appropriate mental and physical readiness.
WHO leadership expressed caution about initiating young children on GLP-1 drugs, questioning the duration and long-term trajectory of such treatments. Officials stated insufficient evidence exists regarding whether these medications can function as temporary interventions before transitioning to dietary approaches in later life, underscoring the organization’s measured approach pending further evidence development.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI